BRAVO, CRUISE studies show benefits of early retinal vein occlusion treatment
Early treatment with ranibizumab significantly improved vision in patients treated for retinal vein occlusion, according to a post-hoc analysis of two major studies.
Data were culled from the BRAVO and CRUISE studies. Patients received Lucentis (ranibizumab, Genentech) 0.3 mg or 0.5 mg for 6 months, then on an as-needed basis (PRN) according to re-treatment protocols.
In the BRAVO study, median time to a gain of 15 letters or more from baseline was 4.8 months for patients who received ranibizumab 0.3 mg, 4 months for those who received ranibizumab 0.5 mg and 12 months for those who received sham injections.
In the CRUISE study, median time to a gain of 15 letters or more from baseline was 5.9 months in the 0.3 mg group, 5.2 months in the 0.5 mg group and 12.2 months in the sham group.
Among patients in the BRAVO study, 71% in the 0.5 mg group, 68% in the 0.3 mg group and 50% in the sham group gained 15 or letters or more from baseline to 12 months.
Of patients in the CRUISE study, 66% in the 0.5 mg group, 61% of those in the 0.3 mg group and 42% of those in the sham group gained 15 or more letters by 12 months.
After 6 months of ranibizumab PRN treatment, 10.8% of patients in BRAVO and 26.2% of those in CRUISE who were initially treated with sham gained 15 or more letters, the authors found.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.